Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-01

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

NCT04714229

Infection, Meningococcal

COMPLETED PHASE1

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

NCT00262002

Prevention of Meningococcal Disease

COMPLETED PHASE2

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

NCT06131554

Meningococcal Meningitis

ACTIVE_NOT_RECRUITING PHASE3

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180

Invasive Meningococcal Disease

COMPLETED PHASE2

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

NCT01823536

Meningococcal Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections, Meningococcal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LHD153R Formulation 1 Group

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.

Group Type EXPERIMENTAL

Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R

Intervention Type BIOLOGICAL

Intramuscular (IM) vaccination of 1 dose of 0.5 mL

LHD153R Formulation 2 Group

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.

Group Type EXPERIMENTAL

Investigational MenC-CRM adjuavnted with 25 ug of LHD153R

Intervention Type BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

LHD153R Formulation 3 Group

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.

Group Type EXPERIMENTAL

Investigational MenC-CRM adjuavnted with 50 ug of LHD153R

Intervention Type BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

LHD153R Formulation 4 Group

Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.

Group Type EXPERIMENTAL

Investigational MenC-CRM adjuavnted with 100 ug of LHD153R

Intervention Type BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

MenC Group

Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.

Group Type ACTIVE_COMPARATOR

Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

Intervention Type BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R

Intramuscular (IM) vaccination of 1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Investigational MenC-CRM adjuavnted with 25 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Investigational MenC-CRM adjuavnted with 50 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Investigational MenC-CRM adjuavnted with 100 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

IM vaccination of 1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female individuals of 18 through 45 years of age on the day of informed consent
2. Healthy volunteers with good physical and mental health status, determined on the basis of the medical history, a physical examination and the results of the screening tests as judged by the investigator
3. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
4. Individuals who can comply with study procedures including follow-up
5. Individuals that are able to understand, read and write German language
6. Females of childbearing potential who are using an effective birth control method which they intend to use for at least 30 days after the study vaccination.

Exclusion Criteria

1. Progressive, unstable or uncontrolled clinical conditions
2. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study
3. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
4. Abnormal function of the immune system
5. Received immunoglobulins or any blood products within 180 days prior to informed consent
6. Received an investigational or non-registered medicinal product within 30 days prior to informed consent or intend to participate in another clinical study at any time during the conduct of this study
7. Vulnerable subjects (e.g. persons kept in detention), study personnel or an immediate family or household member of study personnel, subjects with legal incapacity or limited legal capacity
8. Any relevant deviation from the laboratory parameters at screening as judged by the investigator
9. Previously received any vaccine that included a MenC antigen
10. Previously suspected or confirmed disease caused by N. meningitides
11. Had household contact with and/or intimate exposure to an individual with culture proven MenC
12. A positive serum or urine pregnancy test prior to the study vaccine administration or are currently lactating.
13. A positive drugs-of-abuse test prior to the study vaccine administration;
14. Received any other vaccines within 30 days prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the administration of study vaccines
15. Any other condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes